Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.2% |
| 2 | Technology | 14.19% |
| 3 | Financials | 12.33% |
| 4 | Consumer Staples | 10.22% |
| 5 | Industrials | 9.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2126
Xylem
XYL
$28B
| $2.52M | ﹤0.01% |
45,400
-1,293,400
| -97% | -$67.4M |
|
2127
Westamerica Bancorp
WABC
$1.38B
| $2.51M | ﹤0.01% |
44,831
+1,900
| +4% | +$104K |
|
|
TLP
2128
DELISTED
Transmontaigne
TLP
| $2.51M | ﹤0.01% |
59,724
+42,203
| +241% | +$1.81M |
|
2129
Granite Construction
GVA
$5.55B
| $2.49M | ﹤0.01% |
51,700
-106,100
| -67% | -$5.28M |
|
2130
Grupo SIMEC
SIM
$4.68B
| $2.49M | ﹤0.01% |
232,300
+9,300
| +4% | +$102K |
|
2131
Beazer Homes USA
BZH
$872M
| $2.49M | ﹤0.01% |
181,360
-197,200
| -52% | -$2.55M |
|
|
COVS
2132
DELISTED
Covisint Corporation
COVS
| $2.49M | ﹤0.01% |
1,015,000
+123,600
| +14% | +$258K |
|
|
SAFE
2133
Safehold
SAFE
$1.08B
| $2.48M | ﹤0.01% |
42,397
+11,458
| +37% | +$678K |
|
|
EFC
2134
Ellington Financial
EFC
$1.76B
| $2.48M | ﹤0.01% |
152,970
+46,523
| +44% | +$768K |
|
|
CVLY
2135
DELISTED
Codorus Valley Bancorp Inc
CVLY
| $2.48M | ﹤0.01% |
100,948
+13,234
| +15% | +$309K |
|
|
ARQL
2136
DELISTED
Arqule Inc
ARQL
| $2.48M | ﹤0.01% |
1,996,900
-15,800
| -0.8% | -$17.2K |
|
|
MTLS
2137
Materialise
MTLS
$398M
| $2.48M | ﹤0.01% |
208,500
+113,000
| +118% | +$1.31M |
|
|
LPNT
2138
DELISTED
LifePoint Health, Inc.
LPNT
| $2.47M | ﹤0.01% |
+36,830
| New | +$2.33M |
|
|
CPRX
2139
DELISTED
Catalyst Pharmaceutical
CPRX
| $2.46M | ﹤0.01% |
891,800
+509,400
| +133% | +$1.06M |
|
|
ONDK
2140
DELISTED
On Deck Capital, Inc.
ONDK
| $2.46M | ﹤0.01% |
527,800
+12,800
| +2% | +$54.5K |
|
2141
Comp X International
CIX
$388M
| $2.46M | ﹤0.01% |
161,600
+3,100
| +2% | +$45.2K |
|
2142
Packaging Corp of America
PKG
$22.8B
| $2.45M | ﹤0.01% |
22,000
-22,700
| -51% | -$2.29M |
|
|
NWHM
2143
DELISTED
THE NEW HOME COMPANY INC.
NWHM
| $2.45M | ﹤0.01% |
213,600
+175,800
| +465% | +$1.96M |
|
2144
Clearwater Paper
CLW
$348M
| $2.45M | ﹤0.01% |
+52,325
| New | +$2.53M |
|
2145
AMES National
ATLO
$280M
| $2.44M | ﹤0.01% |
79,723
+4,323
| +6% | +$133K |
|
|
MPX
2146
DELISTED
Marine Products Corp
MPX
| $2.44M | ﹤0.01% |
156,200
-33,407
| -18% | -$431K |
|
2147
Douglas Dynamics
PLOW
$975M
| $2.44M | ﹤0.01% |
74,000
-3,700
| -5% | -$114K |
|
|
SBCP
2148
DELISTED
Sunshine Bancorp, Inc
SBCP
| $2.42M | ﹤0.01% |
113,700
+84,840
| +294% | +$1.85M |
|
|
ENZY
2149
DELISTED
Enzymotec Ltd
ENZY
| $2.42M | ﹤0.01% |
299,000
+10,300
| +4% | +$85.8K |
|
|
KND
2150
DELISTED
Kindred Healthcare
KND
| $2.42M | ﹤0.01% |
207,490
-99,562
| -32% | -$982K |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.